Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Octadecylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.59 |
| ▸ | GSR | P00390 | 1/20 | 0.51 |
| ▸ | RRM1 | P23921 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | OTC | P00480 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octadecylamine SCHEMBL21055685 | 1.00 | GNAI3 (0.59) | GNAI3GNAO1GNAI1GSRRRM1 | |
| Arginine SCHEMBL14742697 | 0.93 | DPP7 (0.54) | GNAI3GNAO1GNAI1RRM1NOD1 | |
| Lycetamine SCHEMBL831216 | 0.93 | GNAI3 (0.74) | GNAI3GNAO1GNAI1GSRRRM1 | |
| Arginine SCHEMBL6239992 | 0.91 | DPP7 (0.53) | GNAI3GNAO1GNAI1GSRRRM1 | |
| Arginine SCHEMBL6242106 | 0.91 | DPP7 (0.53) | GNAI3GNAO1GNAI1GSRRRM1 | |
| Arginine SCHEMBL25278795 | 0.91 | GSR (0.61) | GNAI3GNAO1GNAI1GSROTC | |
| Arginine SCHEMBL1227757 | 0.91 | GSR (0.61) | GNAI3GNAO1GNAI1GSROTC | |
| Arginine SCHEMBL27968223 | 0.90 | GNAI3 (0.49) | GNAI3GNAO1GNAI1GSRRRM1 | |
| Arginine SCHEMBL11660904 | 0.90 | GSR (0.65) | GNAI3GNAO1GNAI1GSROTC | |
| Arginine SCHEMBL9989696 | 0.90 | GSR (0.59) | GNAI3GNAO1GNAI1GSRRRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226211-A9 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131097-A1 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-25 | — | — | US | disclosed |
| US-11926604-B2 | Myelination stimulator compounds, and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-03-12 | — | — | US | disclosed |
| US-20210188792-A1 | MYELINATION STIMULATOR COMPOUNDS, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2021-06-24 | — | — | US | disclosed |
| US-20210161980-A1 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-03 | — | — | US | disclosed |
| EP-3813824-A1 | MYELINATION STIMULATOR COMPOUNDS, AND METHODS OF TREATMENT | University of Florida Research Foundation, Incorporated (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2019217834-A1 | MYELINATION STIMULATOR COMPOUNDS, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019113383-A1 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131097-A1 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | KEAP1, NFE2L2, TFEB | GNAI3 912/4885GNAO1 1049/4885GNAI1 1082/4885 |
| US-20210161980-A1 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | KEAP1, NFE2L2, TFEB | GNAI3 912/4885GNAO1 1049/4885GNAI1 1082/4885 |
| US-11926604-B2 | Myelination stimulator compounds, and methods of treatment | MAG, GAP43, PMP22 | GNAI3 2678/4885GNAO1 935/4885GNAI1 2958/4885 |
| US-20240226211-A9 | SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENT | KEAP1, NFE2L2, TFEB | GNAI3 912/4885GNAO1 1049/4885GNAI1 1082/4885 |
| US-20210188792-A1 | MYELINATION STIMULATOR COMPOUNDS, AND METHODS OF TREATMENT | MAG, GAP43, PMP22 | GNAI3 2678/4885GNAO1 935/4885GNAI1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.